Literature DB >> 20415649

MicroRNA-21: from cancer to cardiovascular disease.

Virginija Jazbutyte1, Thomas Thum.   

Abstract

MicroRNA-21 (miR-21) expression is activated in multiple types of cancers, such as breast, liver, brain, prostate, myometrial cancers but also in cardiovascular diseases. MiR-21 regulates a plethora of target proteins which are involved in cellular survival, apoptosis and cell invasiveness. MiR-21 regulation is complex due to an own promoter that is target for various transcription factors and hormones. The consistent miR-21 overexpression under pathophysiological conditions points to miR-21 as a valuable tool for new therapeutic strategies. In this review, we present and analyze current data about miR-21 expression in various pathologies ranging from cancer to cardiovascular disease. Further, miR-21 regulatory mechanisms and miR-21 downstream targets are discussed. Finally, we highlight the particular role of miR-21 as a therapeutic target in various diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20415649     DOI: 10.2174/138945010791591403

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  91 in total

1.  MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation.

Authors:  Jing Zhou; Kuei-Chun Wang; Wei Wu; Shankar Subramaniam; John Y-J Shyy; Jeng-Jiann Chiu; Julie Y-S Li; Shu Chien
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-02       Impact factor: 11.205

2.  Diagnostic and prognostic value of plasma microRNA deregulation in nasopharyngeal carcinoma.

Authors:  Xiong Liu; Hua-Nan Luo; Wen-Dong Tian; Juan Lu; Gang Li; Lu Wang; Bao Zhang; Bi-Jun Liang; Xiao-Hong Peng; Shao-Xiong Lin; Ying Peng; Xiang-Ping Li
Journal:  Cancer Biol Ther       Date:  2013-08-23       Impact factor: 4.742

Review 3.  MicroRNAs as mediators and therapeutic targets in chronic kidney disease.

Authors:  Johan M Lorenzen; Hermann Haller; Thomas Thum
Journal:  Nat Rev Nephrol       Date:  2011-03-22       Impact factor: 28.314

Review 4.  Roles of Grainyhead-like transcription factors in cancer.

Authors:  S M Frisch; J C Farris; P M Pifer
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

5.  MiR-92a regulates viability and angiogenesis of endothelial cells under oxidative stress.

Authors:  Lan Zhang; Mi Zhou; Gangjian Qin; Neal L Weintraub; Yaoliang Tang
Journal:  Biochem Biophys Res Commun       Date:  2014-03-17       Impact factor: 3.575

Review 6.  Noncoding RNAs in Cardiovascular Disease: Pathological Relevance and Emerging Role as Biomarkers and Therapeutics.

Authors:  Roopesh S Gangwar; Sanjay Rajagopalan; Rama Natarajan; Jeffrey A Deiuliis
Journal:  Am J Hypertens       Date:  2018-01-12       Impact factor: 2.689

Review 7.  [Pathobiology of the microRNA system].

Authors:  K Hussein
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

8.  PEGylation of therapeutic oligonucletides: From linear to highly branched PEG architectures.

Authors:  Xueguang Lu; Ke Zhang
Journal:  Nano Res       Date:  2018-07-06       Impact factor: 8.897

9.  Pilot Study of Serum MicroRNA-21 as a Diagnostic and Prognostic Biomarker in Egyptian Breast Cancer Patients.

Authors:  Eman A Toraih; Eman A Mohammed; Sherif Farrag; Nevene Ramsis; Somaya Hosny
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

10.  Anti-inflammatory effects of miR-21 in the macrophage response to peritonitis.

Authors:  Rebecca Elise Barnett; Daniel J Conklin; Lindsey Ryan; Robert C Keskey; Vikram Ramjee; Ernesto A Sepulveda; Sanjay Srivastava; Aruni Bhatnagar; William G Cheadle
Journal:  J Leukoc Biol       Date:  2015-09-17       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.